ESR1 and breast cancer: We also confirmed that HR+ breast cancer cell-lines [43] were significantly more sensitive to the drugs targeting ESR1 than TNBC samples (P-value = 3.46E-04) using drug sensitivity data of GDSC (Figure 4D).